PE20060996A1 - Polimorfo cci-779 de forma ii y composiciones farmaceuticas - Google Patents
Polimorfo cci-779 de forma ii y composiciones farmaceuticasInfo
- Publication number
- PE20060996A1 PE20060996A1 PE2006000136A PE2006000136A PE20060996A1 PE 20060996 A1 PE20060996 A1 PE 20060996A1 PE 2006000136 A PE2006000136 A PE 2006000136A PE 2006000136 A PE2006000136 A PE 2006000136A PE 20060996 A1 PE20060996 A1 PE 20060996A1
- Authority
- PE
- Peru
- Prior art keywords
- cci
- polymorph
- acetone
- refers
- approximately
- Prior art date
Links
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical group C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 4
- 229960000235 temsirolimus Drugs 0.000 abstract 3
- -1 RAPAMYCIN ESTER Chemical class 0.000 abstract 2
- 239000008259 solid foam Substances 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000007707 calorimetry Methods 0.000 abstract 1
- 230000007123 defense Effects 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65137405P | 2005-02-09 | 2005-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060996A1 true PE20060996A1 (es) | 2006-11-13 |
Family
ID=36570939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000136A PE20060996A1 (es) | 2005-02-09 | 2006-02-03 | Polimorfo cci-779 de forma ii y composiciones farmaceuticas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7442707B2 (https=) |
| EP (1) | EP1856130A1 (https=) |
| JP (1) | JP2008530090A (https=) |
| KR (1) | KR20070107030A (https=) |
| CN (1) | CN101115759A (https=) |
| AR (1) | AR052479A1 (https=) |
| AU (1) | AU2006213061A1 (https=) |
| BR (1) | BRPI0607932A2 (https=) |
| CA (1) | CA2595766A1 (https=) |
| CR (1) | CR9257A (https=) |
| GT (1) | GT200600044A (https=) |
| IL (1) | IL184560A0 (https=) |
| MX (1) | MX2007009590A (https=) |
| NO (1) | NO20073725L (https=) |
| PE (1) | PE20060996A1 (https=) |
| RU (1) | RU2007129264A (https=) |
| TW (1) | TW200638932A (https=) |
| WO (1) | WO2006086172A1 (https=) |
| ZA (1) | ZA200706628B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8551512B2 (en) | 2004-03-22 | 2013-10-08 | Advanced Cardiovascular Systems, Inc. | Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS |
| BRPI0619592A2 (pt) * | 2005-12-07 | 2016-09-06 | Wyeth Corp | métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina |
| AR058282A1 (es) * | 2005-12-07 | 2008-01-30 | Wyeth Corp | Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer. |
| US7622578B2 (en) * | 2005-12-07 | 2009-11-24 | Wyeth | Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| EP2380006A4 (en) * | 2009-01-21 | 2012-05-16 | Biocon Ltd | PROCESS FOR DETERMINING THE SIROLIMUS STABILITY AND METHOD FOR PRODUCING ITS STABLE FORM |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| CN109020995A (zh) * | 2017-06-12 | 2018-12-18 | 鲁南制药集团股份有限公司 | 一种替西罗莫司的晶型物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| BR0211986A (pt) * | 2001-08-22 | 2004-09-28 | Wyeth Corp | 29-enóis de rapamicina |
| MXPA04001523A (es) | 2001-08-22 | 2004-05-31 | Wyeth Corp | Dialdehidos de rapamicina. |
| WO2005010010A1 (en) | 2003-07-16 | 2005-02-03 | Wyeth | Cci-779 isomer c |
| KR20060057605A (ko) | 2003-08-07 | 2006-05-26 | 와이어쓰 | Ｃｃｉ-779의 위치선택적 합성 방법 |
| RU2345999C2 (ru) | 2003-09-03 | 2009-02-10 | Уайт | Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции |
| JP4224115B2 (ja) * | 2004-04-14 | 2009-02-12 | ワイス | ラパマイシン４２−エステル誘導体の位置特異的合成 |
-
2006
- 2006-01-25 CA CA002595766A patent/CA2595766A1/en not_active Abandoned
- 2006-01-25 RU RU2007129264/04A patent/RU2007129264A/ru not_active Application Discontinuation
- 2006-01-25 US US11/339,728 patent/US7442707B2/en not_active Expired - Fee Related
- 2006-01-25 WO PCT/US2006/003098 patent/WO2006086172A1/en not_active Ceased
- 2006-01-25 BR BRPI0607932A patent/BRPI0607932A2/pt not_active IP Right Cessation
- 2006-01-25 JP JP2007555124A patent/JP2008530090A/ja not_active Withdrawn
- 2006-01-25 CN CNA200680004408XA patent/CN101115759A/zh not_active Withdrawn
- 2006-01-25 MX MX2007009590A patent/MX2007009590A/es not_active Application Discontinuation
- 2006-01-25 AU AU2006213061A patent/AU2006213061A1/en not_active Abandoned
- 2006-01-25 EP EP06734012A patent/EP1856130A1/en not_active Withdrawn
- 2006-01-25 KR KR1020077018347A patent/KR20070107030A/ko not_active Withdrawn
- 2006-02-03 PE PE2006000136A patent/PE20060996A1/es not_active Application Discontinuation
- 2006-02-06 TW TW095103902A patent/TW200638932A/zh unknown
- 2006-02-07 GT GT200600044A patent/GT200600044A/es unknown
- 2006-02-08 AR ARP060100451A patent/AR052479A1/es unknown
-
2007
- 2007-07-12 IL IL184560A patent/IL184560A0/en unknown
- 2007-07-18 NO NO20073725A patent/NO20073725L/no not_active Application Discontinuation
- 2007-07-18 CR CR9257A patent/CR9257A/es not_active Application Discontinuation
- 2007-08-08 ZA ZA200706628A patent/ZA200706628B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2595766A1 (en) | 2006-08-17 |
| NO20073725L (no) | 2007-09-05 |
| GT200600044A (es) | 2006-11-09 |
| AU2006213061A1 (en) | 2006-08-17 |
| US7442707B2 (en) | 2008-10-28 |
| AR052479A1 (es) | 2007-03-21 |
| MX2007009590A (es) | 2007-09-12 |
| CR9257A (es) | 2007-11-23 |
| WO2006086172A1 (en) | 2006-08-17 |
| ZA200706628B (en) | 2010-01-27 |
| JP2008530090A (ja) | 2008-08-07 |
| TW200638932A (en) | 2006-11-16 |
| CN101115759A (zh) | 2008-01-30 |
| EP1856130A1 (en) | 2007-11-21 |
| KR20070107030A (ko) | 2007-11-06 |
| RU2007129264A (ru) | 2009-03-20 |
| BRPI0607932A2 (pt) | 2016-11-08 |
| US20060178392A1 (en) | 2006-08-10 |
| IL184560A0 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008002794A1 (es) | Compuestos derivados de dihidropirimidina-2,4-(1h,3h)-diona; formas cristalinas, compuestos intermediarios; procedimiento de preparación de los compuestos intermediarios, composición farmacéutica; y su uso util para tratar hepatitis c en un mamífero. | |
| CR10095A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CL2014000363A1 (es) | Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros. | |
| CU24100B1 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
| HN2006041184A (es) | Metodos y estuches para dosificar nucleosidos antivirales beta-d-2 3- didehydro-2 , 3-dideoxy 5- fluorocytidina | |
| WO2015058163A3 (en) | Heteromaromatic compounds useful for the treatment of prolferative diseases | |
| CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
| AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| AR061730A1 (es) | Estructuras de cristal de inhibidores sglt2 y procesos para preparar los mismos | |
| TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
| ECSP078055A (es) | Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas | |
| PA8593001A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| PE20170663A1 (es) | Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| BRPI0813044A2 (pt) | "composto, composição fungicida e método para o controle do fungo fitopatogênico de culturas" | |
| EA201101695A1 (ru) | Усовершенствованный способ синтеза пирфенидона | |
| AR057531A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina y composicion farmaceutica | |
| WO2008016738A3 (en) | Antibacterial agents and related screening methods using small molecule macroarrays | |
| PE20060996A1 (es) | Polimorfo cci-779 de forma ii y composiciones farmaceuticas | |
| CR10654A (es) | Agentes que comprenden compuestos marcados con 18f y metodos relacionados | |
| EA201170282A1 (ru) | Фунгицидные n-циколоалкил-n-бифенилметилкарбоксамидные производные | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| DOP2006000243A (es) | Derivados de pirazina | |
| NZ592429A (en) | PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |